The first, pan-European guidelines to be published on the treatment of valvular heart disease, diabetes and cardiovascular diseases have made a series of new recommendations which experts hope will contribute to improving the outcome of patients with these diseases.
Increasing the ability to identify sentinel nodes?the very first lymph nodes that trap cancer cells draining away from a breast lesion site?has a major impact in the treatment and outcome of breast cancer patients, possibly eliminating the need for unnecessary and painful surgery.
Women who develop high blood pressure during pregnancy are more likely to develop increased coronary calcification later in life than those who maintained a normal blood pressure.
An American Heart Association national study published in the January 2007 issue (Vol. 16, No. 1) of Journal of Women?s Health demonstrated a continuing disparity in awareness and knowledge about heart disease and stroke across racial/ethnic lines, highlighting the need to target educational efforts to black and Hispanic women in particular.
The Society for Cardiovascular Angiography and Interventions (SCAI), a leading organization for interventional cardiologists, today released a document recommending the adoption of stringent quality standards by those who perform percutaneous coronary intervention (PCI) in hospitals not equipped for cardiac surgery.
A new supplemental therapy that teaches pain coping and biofeedback skills can reduce pain, the potential for chronic pain and health-care costs for millions of Americans suffering from a common jaw disorder, UT Southwestern Medical Center researchers have found.
Adults have experienced increased rates of chronic diseases such as hypertension since Hurricane Katrina, and children in the area have experienced increased rates of mental health problems.
The U.S. Food and Drug Administration (FDA) announced the approval of Antihemophilic Factor/von Willebrand Factor Complex (Human), Alphanate. The product is approved for patients undergoing surgery or invasive procedures with von Willebrand disease (vWD) in whom the hormone desmopressin is either ineffective or contraindicated.
The U.S. Food and Drug Administration (FDA) in the U.S. Department of Health and Human Services and the Veterans Health Administration (VHA) in the U.S. Department of Veterans Affairs (VA) announced that they have signed a memorandum of understanding (MOU) to share information and expertise related to the review and use of FDA-regulated drugs, biologics and medical devices (medical products).
The U.S. Food and Drug Administration (FDA) outlined a comprehensive commitment to the safety of drugs and other medical products.